Esomeprazole – S-isomer of omeprazole with more favorable pharmacological properties and stronger pharmacodynamic effect
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in:
Gastroent Hepatol 2018; 72(2): 179-181
Category:
Drug Profile
doi:
https://doi.org/10.14735/amgh2018179
Sources
1. Martínek J, Lukáš M. Inhibitory protonové pumpy – up to date. Gastroent Hepatol 2011; 65 (6): 331–342.
2. Špičák J. Inhibitory protonové pumpy: vedlejší účinky a interakce. Gastroent Hepatol 2013; 67 (4): 289–297.
3. Souhrn údajů o přípravku Pylera. [online]. Dostupné z: www.sukl.cz.
4. Heribanová L. Extraezofageální a gastroezofageální reflux – vztah k astma bronchiale. Gastroent Hepatol 2016; 70 (5): 438–442. doi: 10.14735/amgh2016438.
5. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2 (2): 132–139.
6. Miehlke S, Madisch A, Kirsch C et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21 (8) : 963–967.
Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery Internal medicine Nutritive therapist ObesitologyArticle was published in
Gastroenterology and Hepatology
2018 Issue 2
Most read in this issue
- Terlipressin remains indispensable in two indications
- Guidelines of the Czech Society of Hepatology for diagnosis and treatment of primary biliary cholangitis
- Hepatic cyst infection as a source of sepsis in liver polycystosis
- A rare cause of increased abdominal size